Personal experience of therapy individualization with prolonged FVIII in an adolescent with severe hemophilia A and hemophilic arthropathy

Abstract

Summary. This article presents a clinical case of an adolescent with severe hemophilia A and hemophilic arthropathy, who underwent indi- vidualized prophylactic treatment with extended half-life factor (F) VIII (efmoroctocog alfa). Transition to a pharmacokinetically tailored regimen, based on residual FVIII activity and the patient’s physical activity level, stabilized joint condition and regression of inflammatory changes as confirmed by magnetic resonance imaging. The findings support the effectiveness of a personalized approach combining early detection of subclinical joint damage and optimization of extended half-life FVIII therapy, resulting in improved joint health and quality of life.

For citation: Lemazina E.N., Shangareeva G.D., Gubaydullina D.G., Sadykov M.M. Personal experience of therapy individualization with prolonged FVIII in an adolescent with severe hemophilia A and hemophilic arthropathy. Tromboz, gemostaz i reologiya. 2025;(4):95–100. (In Russ.).

References

1.      van Vulpen L.F.D., Holstein K., Martinoli C. Joint disease in haemophilia: Pathophysiology, pain and imaging. Haemophilia. 2018;24 Suppl 6:44–9. DOI: 10.1111/hae.13449.

2.      Polyanskaya T.Yu., Zorenko V.Yu., Karpov E.E. Modern concepts of the pathogenesis of hemophilic arthropathy. Voprosy gematologii/ onkologii i immunopatologii v pediatrii. 2015;14(3):5–13. (In Russ.).

3.      O’Hara J., Walsh S., Camp C. et al. The impact of severe haemo‐ philia and the presence of target joints on health‐related qua‐ lity‐of‐life. Health Qual Life Outcomes. 2018;16(1):84. DOI: 10.1186/ s12955‐018‐0908‐9.

4.      Zhu H., Meng Y., Tong P., Zhang S. Pathological mechanism of joint destruction in haemophilic arthropathy. Mol Biol Rep. 2021;48(1):969–74. DOI: 10.1007/s11033‐020‐06052‐8.

5.      Wilkins R.A., Stephensen D., Siddle H. et al. Twelve‐month preva‐ lence of haemarthrosis and joint disease using the Haemophilia Joint Health score: evaluation of the UK National Haemophilia Database and Haemtrack patient reported data: an observational study. BMJ Open. 2022;12(1):e052358. DOI: 10.1136/bmjopen‐2021‐052358.

6.      Wei Z., Ou L., Chai S. et al. Global trends in hemophilic arthropa‐ thy research: a bibliometric and visualization analysis. Front Med (Lausanne). 2025;12:1556906. DOI: 10.3389/fmed.2025.1556906.

7.      Jansen N.W., Roosendaal G., Bijlsma J.W. et al. Exposure of human cartilage tissue to low concentrations of blood for a short period of time leads to prolonged cartilage damage: an in vitro study. Arthritis Rheum. 2007;56(1):199–207. DOI: 10.1002/art.22304.

8.      Hooiveld M., Roosendaal G., Wenting M. et al. Short‐term exposure  2003;162(3):943–51. DOI: 10.1016/S0002‐9440(10)63889‐8.

9.      Zhang L., Guo J., Wei S. et al. The prediction of haemophilic arthropathy progression based on MRI findings and clinical characteristics. Orphanet J Rare Dis. 2025;20(1):190. DOI: 10.1186/ s13023‐025‐03716‐1.

10.  Gualtierotti R., Giachi A., Truma A. et al. Assessing joint health in haemophilia patients: the combined value of physical examination and ultrasound imaging. Haemophilia. 2024;30(4):1018–24. DOI: 10.1111/hae.15030.